LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro
Preprint
Abstract
Objective: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen accountable for the coronavirus disease 2019 (COVID-19) pandemic. Viral entry via binding of the receptor binding domain (RBD) located within the S1 subunit of the SARS-CoV-2 Spike (S) protein to its target receptor angiotensin converting enzyme (ACE) 2 is a key step in cell infection. The efficient transition of the virus is linked to a unique protein called open reading frame (ORF) 8. As SARS-CoV-2 infections can develop into life-threatening lower respiratory syndromes, effective therapy options are urgently needed. Several publications propose vitamin D treatment, although its mode of action against COVID-19 is not fully elucidated. It is speculated that vitamin D’s beneficial effects are mediated by up-regulating LL-37, a well-known antimicrobial peptide with antiviral effects. Methods: Recombinantly expressed SARS-CoV-2 S protein, the extended S1 subunit (S1e), the S2 subunit (S2), the receptor binding domain (RBD), and ORF8 were used for surface plasmon resonance (SPR) studies to investigate LL-37’s ability to bind to SARS-CoV-2 proteins and to localize its binding site within the S protein. Binding competition studies were conducted to confirm an inhibitory action of LL-37 on the attachment of SARS-CoV-2 S protein to its entry receptor ACE2. Results: We could show that LL-37 binds to SARS-CoV-2 S protein (LL-37/S Strep K D = 410 nM, LL-37/S His K D = 410 nM) with the same affinity, as SARS-CoV-2 binds to hACE2 (hACE2/S Strep K D = 370 nM, hACE2/S His K D = 370 nM). The binding is not restricted to the RBD of the S protein, but rather distributed along the entire length of the protein. Interaction between LL-37 and ORF8 was detected with a K D of 290 nM. Further, inhibition of the binding of S Strep (IC 50 = 740 nM), S1e (IC 50 = 170 nM), and RBD (IC 50 = 130 nM) to hACE2 by LL-37 was demonstrated. Conclusions: We have revealed a biochemical link between vitamin D, LL-37, and COVID-19 severity. SPR analysis demonstrated that LL-37 binds to SARS-CoV-2 S protein and inhibits binding to its receptor hACE2, and most likely viral entry into the cell. This study supports the prophylactic use of vitamin D to induce LL-37 that protects from SARS-CoV-2 infection, and the therapeutic administration of vitamin D for the treatment of COVID-19 patients. Further, our results provide evidence that the direct use of LL-37 by inhalation and systemic application may reduce the severity of COVID-19.Keywords
This publication has 48 references indexed in Scilit:
- Antiviral Activity and Increased Host Defense against Influenza Infection Elicited by the Human Cathelicidin LL-37PLOS ONE, 2011
- Vitamin D and the anti-viral stateJournal of Clinical Virology, 2011
- Identification of a New Region of SARS-CoV S Protein Critical for Viral EntryJournal of Molecular Biology, 2009
- Convergence of IL-1β and VDR Activation Pathways in Human TLR2/1-Induced Antimicrobial ResponsesPLOS ONE, 2009
- Coronaviruses post-SARS: update on replication and pathogenesisNature Reviews Microbiology, 2009
- A New Model for Growth Factor Activation: Type II Receptors Compete with the Prodomain for BMP-7Journal of Molecular Biology, 2008
- Targeting of Bone Morphogenetic Protein Growth Factor Complexes to FibrillinJournal of Biological Chemistry, 2008
- Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D3Journal of Cystic Fibrosis, 2007
- Antimicrobial Peptide LL‐37 Internalized by Immature Human Dendritic Cells Alters their PhenotypeScandinavian Journal of Immunology, 2006
- Antimicrobial Peptide LL-37 is Upregulated in Chronic Nasal Inflammatory DiseaseActa Oto-Laryngologica, 2003